Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation

Rafael Holdings, Inc. (RFL) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/15/2021 8-K Quarterly results
07/14/2021 8-K/A Quarterly results
07/09/2021 8-K Quarterly results
06/22/2021 3 McCamish Mark Anthony (Director) has filed a Form 3 on Rafael Holdings, Inc.
06/22/2021 3 Klinger Shannon Thyme (Director) has filed a Form 3 on Rafael Holdings, Inc.
06/21/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Investor Presentations"
06/21/2021 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among Holdings, Merger Sub I, Merger Sub II and Pharma",
"Form of Lock-Up Agreement",
"Form of Voting Agreement",
"Form of Support Agreement",
"Form of Convertible Note Cancellation Agreement",
"Form of Altira Acquisition Agreement",
"Form of Letter of Transmittal",
"# # #"
06/18/2021 EFFECT Form EFFECT - Notice of Effectiveness:
06/14/2021 10-Q Quarterly Report for the period ended April 30, 2021
06/14/2021 8-K Quarterly results
06/08/2021 EFFECT Form EFFECT - Notice of Effectiveness:
06/07/2021 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/28/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/27/2021 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/26/2021 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/10/2021 3 Form 3 - Initial statement of beneficial ownership of securities:
04/19/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/14/2021 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/30/2021 GN Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
03/24/2021 EFFECT Form EFFECT - Notice of Effectiveness:
03/18/2021 3 CONKLING WILLIAM (Chief Commercial Officer) has filed a Form 3 on Rafael Holdings, Inc.
03/17/2021 10-Q Quarterly Report for the period ended January 31, 2021
03/17/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Rafael Holdings Reports Second Quarter Fiscal Year 2021 Results"
03/11/2021 8-K Quarterly results
03/11/2021 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
02/24/2021 S-3 Form S-3 - Registration statement under Securities Act of 1933:
02/12/2021 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2021 GN LipoMedix Announces Manufacturing Agreement with ForDoz for Promitil®
02/08/2021 RW Form RW - Registration Withdrawal Request:
01/28/2021 8-K Other Events
01/20/2021 S-3 Form S-3 - Registration statement under Securities Act of 1933:
01/19/2021 GN Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference
01/19/2021 8-K Quarterly results
01/14/2021 3 JONAS RACHEL (Director) has filed a Form 3 on Rafael Holdings, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy